



Seoul International Digestive Disease Symposium 2024

In Conjunction with the Annual Meeting of the Korean Society of Gastroenterology

April 20-21, 2024

Grand Walkerhill Seoul, Korea

"Pioneering the future of digestive diseases"



SIDDS 2024

Name	Jae Seung Lee
Affiliation	Department of Internal Medicine, Yonsei University College of Medicine
Country	Republic of Korea
Major Field	Hepatology

Educational Background

2004.3-2010.2 Yonsei University College of Medicine, Korea

2018.3-2024.2 Department of Medicine, The Graduate School, Yonsei University, Korea

Professional Experience

2020.3-	Clinical Assistant Professor Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
2010-	Member of the Korean Association of Internal Medicine
2019-	Member of the Korean Society of Gastrointestinal Endoscopy
2019-	Member of the Korean Association of the Study of the Liver (KASL)
2023.12-	Member of the Academic Committee of the KASL, Current
2023.12-	Member of the Research Committee of the KASL, Current
2023-	Member of the Korean Liver Cancer Association (KLCA)
2023.12-	Member of the Planning Committee of the KLCA, Current
2023-	Member of the Korean Association of Clinical Ultrasound
2023-	Member of the Publication Committee of the Korean Association of Clinical Ultrasound, Current

Main Scientific Publications

1. Lee JS, Jung CY, Lee JI, Ahn SH, Kim BS, Kim SU. Comparison of decline in renal function between patients with chronic hepatitis B with or without antiviral therapy. *Aliment Pharmacol Ther.* 2023 Jul;58(1):99-109. doi: 10.1111/apt.17532. Epub 2023 Apr 28. PMID: 37114501.
2. Lee JS, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, Jang JY, Park SY, Lee HW, Lee CK, Kim SU. Comparison of FibroScan-Aspartate Aminotransferase (FAST) Score and Other Non-invasive Surrogates in Predicting High-Risk Non-alcoholic Steatohepatitis Criteria. *Front Med (Lausanne).* 2022 Apr 14;9:869190. doi: 10.3389/fmed.2022.869190. PMID: 35492369; PMCID: PMC9048204.
3. Lee JS, Lee HW, Lim TS, Min IK, Lee HW, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK. External Validation of the FSAC Model Using On-Therapy Changes in Noninvasive Fibrosis Markers in Patients with Chronic Hepatitis B: A Multicenter Study. *Cancers (Basel).* 2022 Jan 29;14(3):711. doi: 10.3390/cancers14030711. PMID: 35158982; PMCID: PMC8833581.
4. Lee JS, Lee HW, Lim TS, Shin HJ, Lee HW, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK. Novel Liver Stiffness-Based Nomogram for Predicting Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis B Virus Infection Initiating Antiviral Therapy. *Cancers (Basel).* 2021 Nov 23;13(23):5892. doi: 10.3390/cancers13235892. PMID: 34885000; PMCID: PMC8656676.



5. Lee JS, Sinn DH, Park SY, Shin HJ, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, Oh JH, Lee JI, Kim SU. Liver Stiffness-Based Risk Prediction Model for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. *Cancers (Basel)*. 2021 Sep 11;13(18):4567. doi: 10.3390/cancers13184567. PMID: 34572795; PMCID: PMC8472221.
6. Lee JS, Choi HJ, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, Kim SU. Screening, confirmation, and treatment rates of hepatitis C virus infection in a tertiary academic medical center in South Korea. *J Gastroenterol Hepatol*. 2021 Sep;36(9):2479-2485. doi: 10.1111/jgh.15514. Epub 2021 Apr 12. PMID: 33788314.
7. Baatarkhuu O, Lee JS (Co-primary), Amarsanaa J, Kim DY, Ahn SH, Naranzul N, Enkhtuya D, Choijamts N, Batbayar P, Otgonbayar R, Saruul BU, Gantuul C, Gegebadrakh B, Tuvshinbayar N, Badamsuren D, Ulzmaa G, Otgonbold J, Han KH. Efficacy and safety of ledipasvir/sofosbuvir in 5,028 Mongolian patients infected with genotype 1 hepatitis C virus: A multicenter study. *Clin Mol Hepatol*. 2021 Jan;27(1):125-135.
8. Lee JS, Kim BK, Kim SU, Park JY, Ahn SH, Seong JS, Han KH, Kim DY. A survey on transarterial chemoembolization refractoriness and a real-world treatment pattern for hepatocellular carcinoma in Korea. *Clin Mol Hepatol*. 2020 Jan;26(1):24-32.
9. Lee JS, Cho IR, Lee HW, Jeon MY, Lim TS, Baatarkhuu O, Kim DY, Han KH, Park JY. Conditional Survival Estimates Improve Over Time for Patients with Hepatocellular Carcinoma: An Analysis for Nationwide Korea Cancer Registry Database. *Cancer Res Treat*. 2019 Oct;51(4):1347-1356.
10. Lee JS, Choi HJ, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Baek SE, Chung YE, Park MS, Kim MJ, Rhee H, Kim SU. The Modified Response Evaluation Criteria in Solid Tumors (RECIST) Yield a More Accurate Prognoses Than the RECIST 1.1 in Hepatocellular Carcinoma Treated with Transarterial Radioembolization. *Gut Liver*. 2020 Nov 15;14(6):765-774.